Cryptococcus neoformansin Organ Transplant Recipients: Impact of Calcineurin‐Inhibitor Agents on Mortality
Open Access
- 1 March 2007
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 195 (5), 756-764
- https://doi.org/10.1086/511438
Abstract
Variables influencing the risk of dissemination and outcome of Cryptococcus neoformans infection were assessed in 111 organ transplant recipients with cryptococcosis in a prospective, multicenter, international study. Sixtyone percent (68/111) of the patients had disseminated infection. The risk of disseminated cryptococcosis was significantly higher for liver transplant recipients (adjusted hazard ratio [HR], 6.65; P=.048). The overall mortality rate at 90 days was 14% (16/111). The mortality rate was higher in patients with abnormal mental status (P=.023), renal failure at baseline (P=.028), fungemia (P=.006), and disseminated infection (P=.035) and was lower in those receiving a calcineurin-inhibitor agent (P=.003). In amultivariable analysis, the receipt of a calcineurin-inhibitor agent was independently associated with a lower mortality (adjusted HR, 0.21; P=.008), and renal failure at baseline with a higher mortality rate (adjusted HR, 3.14; P=.037). Thus, outcome in transplant recipients with cryptococcosis appears to be influenced by the type of immunosuppressive agent employed. Additionally, discerning the basis for transplant type-specific differences in disease severity has implications relevant for yielding further insights into the pathogenesis of C. neoformans infection in transplant recipients.Keywords
This publication has 47 references indexed in Scilit:
- Serologic Evidence forCryptococcus neoformansInfection in Early ChildhoodPediatrics, 2001
- HYPOGAMMAGLOBULINEMIA IN LUNG TRANSPLANT RECIPIENTSTransplantation, 2001
- Spectrum of Aspergillus Infection in Lung Transplant RecipientsChest, 2001
- Identification and characterization of a highly conserved calcineurin binding protein, CBP1/calcipressin, inCryptococcus neoformansThe EMBO Journal, 2000
- Synergistic Antifungal Activities of Bafilomycin A 1 , Fluconazole, and the Pneumocandin MK-0991/Caspofungin Acetate (L-743,873) with Calcineurin Inhibitors FK506 and L-685,818 against Cryptococcus neoformansAntimicrobial Agents and Chemotherapy, 2000
- Evidence of Zoonotic Transmission ofCryptococcus neoformansfrom a Pet Cockatoo to an Immunocompromised PatientAnnals of Internal Medicine, 2000
- Comparison of the Roles of Calcineurin in Physiology and Virulence in Serotype D and Serotype A Strains of Cryptococcus neoformansInfection and Immunity, 2000
- Immunosuppressive and Nonimmunosuppressive Cyclosporine Analogs Are Toxic to the Opportunistic Fungal Pathogen Cryptococcus neoformans via Cyclophilin-Dependent Inhibition of CalcineurinAntimicrobial Agents and Chemotherapy, 2000
- Antibodies to theCryptococcus neoformanscapsular glucuronoxylomannan are ubiquitous in serum from HIV+ and HIV− individualsClinical and Experimental Immunology, 1995
- Cryptococcosis in renal allograft recipients.1994